Results 361 to 370 of about 7,331,516 (404)
Some of the next articles are maybe not open access.
Protein-Mediated Membrane Fusion
Annual Review of Biophysics and Biophysical Chemistry, 1989PERSPECTIVES AND OVERVIEW 187 GEN ERAL CON CEPTS 188 Fusion Versus Fission 188 Endoplasmic and Exoplasmic Fusion Events 189 Tightness of Fusion 190 PHYSICAL FORCES BETWEEN MEMBRAN ES ........ 190 FUSION ASSAyS 191 LlPOSOMES AS TARGET MEMBRANES 192 EXOPLASMIC FUSION 193 Influenza Virus Fusion 193 Acid-Induced Conformational Change in ...
Ari Helenius, T Stegmann, Robert W. Doms
openaire +3 more sources
Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.
Science, 1994The 2;5 chromosomal translocation occurs in most anaplastic large-cell non-Hodgkin's lymphomas arising from activated T lymphocytes. This rearrangement was shown to fuse the NPM nucleolar phosphoprotein gene on chromosome 5q35 to a previously ...
S. Morris +6 more
semanticscholar +1 more source
Bioluminescent Immunoassay with a Protein A-Luciferase Fusion Protein
Analytical Biochemistry, 1993Protein A and firefly luciferase were genetically fused and the resulting fusion protein was applied to a bioluminescent immunoassay. The gene fusion plasmid, pMALU2, was constructed by inserting the structural gene of luciferase into a protein A expression vector, and was expressed in Escherichia coli.
T. Iwai +3 more
openaire +3 more sources
2016
Albumin fusion technology can improve the blood retention properties of protein-based pharmaceutics that have a short circulation half-life. The procedure consists of fusing the HSA gene with the gene for a therapeutic protein or peptide, thus permitting the existing recombinant protein therapeutics to be reengineered using albumin as a suitable and ...
Victor Tuan Giam Chuang +2 more
openaire +2 more sources
Albumin fusion technology can improve the blood retention properties of protein-based pharmaceutics that have a short circulation half-life. The procedure consists of fusing the HSA gene with the gene for a therapeutic protein or peptide, thus permitting the existing recombinant protein therapeutics to be reengineered using albumin as a suitable and ...
Victor Tuan Giam Chuang +2 more
openaire +2 more sources
Quantitative lmmunoblotting with Fusion Proteins
2003The development of vaccines against HIV-1 is currently hindered by incomplete understanding of correlates of protective immunity (1-3). Experiments are necessary to measure immune responses in sufficiently fine detail that specific protective responses can be discerned from those that are irrelevant or harmful.
Lawrence D. Loomis-Price +1 more
openaire +3 more sources
Protein conjugates and fusion proteins as ocular therapeutics
Drug Discovery Today, 2019Long-acting delivery (LAD) of ocular therapeutics has potential to improve the standard of care for ocular diseases, such as age-related macular degeneration (AMD), by increasing patient compliance and reducing overall treatment burden on patients and healthcare providers.
Shrenik C. Mehta +2 more
openaire +3 more sources
2018
IgG-based therapeutics has become an increasingly important category of the over two hundred biopharmaceutical products approved in the USA and the EU by late 2014. While a large percentage of this consists of monoclonal antibodies, Fc fusion proteins make up an important class of IgG-based biotechnology drugs.
Dean Pettit, Carole Heath
openaire +2 more sources
IgG-based therapeutics has become an increasingly important category of the over two hundred biopharmaceutical products approved in the USA and the EU by late 2014. While a large percentage of this consists of monoclonal antibodies, Fc fusion proteins make up an important class of IgG-based biotechnology drugs.
Dean Pettit, Carole Heath
openaire +2 more sources
Diphtheria Toxin Fusion Proteins
1998Two different approaches have been undertaken to develop targeted biomolecules for therapeutics. The first was the construction of immunotoxins consisting of monoclonal antibodies chemically linked through a disulfide bond to a plant or bacterial toxin or radionuclide.
James G. Krueger +4 more
openaire +3 more sources
Preparation of Insoluble GST Fusion Proteins
Cold Spring Harbor Protocols, 2009INTRODUCTIONA wide variety of plasmid vectors are commercially available for the production of fusion proteins in bacterial cells. Most are also designed to incorporate a tag that allows affinity purification of the expressed fusion protein from bacterial cell extracts.
Richard G. Fehon, Ilaria Rebay
openaire +4 more sources
Cytokine Fusion Protein Treatment
2002Mice suffering from melanoma can be cured by treatment with a recombinant antibody-lymphotoxin-alpha fusion protein. In order to characterize the involvement of T cells in this syngeneic tumor model, the T cell receptor repertoire was analyzed both quantitatively and qualitatively.
Jürgen C. Becker +4 more
openaire +3 more sources